YAKULT HONSHA CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1955-01-29
- Employees
- 29.6K
- Market Cap
- -
- Website
- http://www.yakult.co.jp
Clinical Trials
58
Active:0
Completed:17
Trial Phases
5 Phases
Phase 1:20
Phase 2:12
Phase 3:4
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (55 trials with phase data)• Click on a phase to view related trials
Phase 1
20 (36.4%)Not Applicable
14 (25.5%)Phase 2
12 (21.8%)phase_1_2
4 (7.3%)Phase 3
4 (7.3%)Phase 4
1 (1.8%)Lactobacillus Casei Strain Shirota Fermented Milk for Alleviating Hard Stools in Vietnam
Not Applicable
Completed
- Conditions
- Constipation
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Yakult Honsha Co., LTD
- Target Recruit Count
- 51
- Registration Number
- NCT05982743
- Locations
- 🇻🇳
Bach Mai Hospital, Hanoi, Vietnam
Probiotics on Immune Function and Intestinal Microbiota in Astronauts Under Closed Microgravity Environment
Not Applicable
- Conditions
- Immune Function and Intestinal Microbiota
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Yakult Honsha Co., LTD
- Target Recruit Count
- 10
- Registration Number
- NCT02618005
- Locations
- 🇯🇵
Japan Aerospace Exploration Agency, Ibaraki, Japan
Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Yakult Honsha Co., LTD
- Target Recruit Count
- 179
- Registration Number
- NCT02400788
Efficacy Evaluation of Probiotic Product on Bowel Habits in Healthy Subjects
Not Applicable
Completed
- Conditions
- Constipation
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Yakult Honsha Co., LTD
- Target Recruit Count
- 238
- Registration Number
- NCT01375712
- Locations
- 🇩🇪
Harrison Clinical Research Deutschland GmbH, Munich, Germany
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Cancer
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Yakult Honsha Co., LTD
- Target Recruit Count
- 40
- Registration Number
- NCT00364143
- Locations
- 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
News
No news found